Septerna, Inc. (SEPN) Research

Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.

Open Septerna, Inc. (SEPN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.